- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A, Von Willebrand Disease, Type 2M, Von Willebrand Disease, Type 2N
- Interventions
- Clinical outcomes of patients with VWD, Type 1, Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3
- Other
- Lead sponsor
- Hemab ApS
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 42
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia A, Congenital
- Interventions
- Alphanate
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- rVWF, rFVIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more
- Conditions
- Von Willebrand Factor Deficiency
- Interventions
- Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
- Conditions
- Von Willebrand Diseases
- Interventions
- Von Willebrand Factor-Containing Product
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 66 Months and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
- Interventions
- ARC1779 Injection, Placebo (normal saline)
- Drug
- Lead sponsor
- Archemix Corp.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • Houston, Texas
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
- Conditions
- Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Hypertrophic Cardiomyopathy, Tricuspid Valve Insufficiency
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Haemophilia A
- Interventions
- Not listed
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Miami, Florida • New Orleans, Louisiana • St Louis, Missouri + 2 more
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Vonicog Alfa, ADVATE
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Orlando, Florida • Peoria, Illinois + 9 more
- Conditions
- Liver Transplant Surgery
- Interventions
- Cryoprecipitate Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF)
- Biological
- Lead sponsor
- Ezeldeen Abuelkasem
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
- Interventions
- ARC 1779 Placebo, ARC1779 Injection
- Drug
- Lead sponsor
- Archemix Corp.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
- Conditions
- Liver Transplant Surgery
- Interventions
- Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF)
- Biological
- Lead sponsor
- Trauma Hemostatis and Oxygenation Research (THOR) Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Von Willebrand Disease
- Interventions
- Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 10
- States / cities
- Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
- Conditions
- Von Willebrand Disease
- Interventions
- Vonicog alfa, Antihemophilic Factor (Recombinant)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
- Conditions
- Hemophilia A
- Interventions
- PLASMA DERIVED Factor VIII, Recombinant FVIII
- Drug
- Lead sponsor
- Fondazione Angelo Bianchi Bonomi
- Other
- Eligibility
- 1 Minute to 6 Years · Male only
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Von Willebrand Disease
- Interventions
- Wilate
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana